Sofinnova Investments’s Immunovant IMVT Stock Holding History

Sofinnova Investments’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-222,553	Closed	-$9.38M	–	79
2023 Q4	$9.38M	Buy	222,553 +82,668	+59%	+$3.04M	0.52%	36
2023 Q3	$5.37M	Buy	+139,885	New	+$3.16M	0.34%	47
2020 Q3	–	Sell	-40,513	Closed	-$987K	–	76
2020 Q2	$987K	Buy	+40,513	New	+$868K	0.06%	71

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Sofinnova Investments's IMVT Position: Q1 2024 in Review

Sofinnova Investments sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 222,553 shares — an estimated $9.38M sold.

Sofinnova Investments first reported a position in IMVT in Q2 2020 and held it in 3 quarters. The position peaked at $9.38M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Sofinnova Investments reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Sofinnova Investments sold 222,553 Immunovant shares in Q1 2024, an estimated $9.38M.
Sofinnova Investments first reported a position in Immunovant in Q2 2020 and held it in 3 quarters.
Sofinnova Investments's Immunovant position peaked at $9.38M in Q4 2023.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.